AssetMark Inc
CSTL icon

AssetMark Inc’s Castle Biosciences CSTL Stock Holding History

AssetMark Inc’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$142K Buy
5,779
+492
+9% +$16.1K ﹤0.01% 1429
2025
Q4 		$206K Sell
5,287
-418
-7% -$13.5K ﹤0.01% 1302
2025
Q3 		$130K Buy
5,705
+1,158
+25% +$23.5K ﹤0.01% 1365
2025
Q2 		$92.8K Buy
4,547
+567
+14% +$10.5K ﹤0.01% 1389
2025
Q1 		$79.7K Sell
3,980
-432
-10% -$10.7K ﹤0.01% 1333
2024
Q4 		$118K Sell
4,412
-800
-15% -$24.4K ﹤0.01% 1209
2024
Q3 		$149K Buy
5,212
+748
+17% +$19K ﹤0.01% 1080
2024
Q2 		$97.2K Buy
4,464
+506
+13% +$11.3K ﹤0.01% 1113
2024
Q1 		$87.7K Sell
3,958
-778
-16% -$16.9K ﹤0.01% 1066
2023
Q4 		$102K Buy
4,736
+832
+21% +$14.6K ﹤0.01% 1031
2023
Q3 		$65.9K Buy
3,904
+994
+34% +$17.4K ﹤0.01% 1043
2023
Q2 		$39.9K Buy
2,910
+672
+30% +$13.6K ﹤0.01% 1130
2023
Q1 		$50.8K Buy
2,238
+738
+49% +$18K ﹤0.01% 1031
2022
Q4 		$35.3K Buy
1,500
+1,025
+216% +$23.8K ﹤0.01% 1113
2022
Q3 		$12K Hold
475
– – ﹤0.01% 1205
2022
Q2 		$10K Buy
475
+375
+375% +$8.71K ﹤0.01% 1217
2022
Q1 		$4K Hold
100
– – ﹤0.01% 1309
2021
Q4 		$4K Sell
100
-225
-69% -$11.8K ﹤0.01% 1263
2021
Q3 		$22K Hold
325
– – ﹤0.01% 923
2021
Q2 		$24K Hold
325
– – ﹤0.01% 871
2021
Q1 		$22K Hold
325
– – ﹤0.01% 852
2020
Q4 		$22K Buy
+325
New +$17.6K ﹤0.01% 834

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AssetMark Inc's CSTL Position: Q1 2026 in Review

AssetMark Inc increased its Castle Biosciences (CSTL) stake by 9.3% in Q1 2026, buying an estimated $16.1K and bringing the position to 5,779 shares worth $142K. The position accounts for ﹤0.01% of the portfolio, ranked #1429.

AssetMark Inc first reported a position in CSTL in Q4 2020 and has held it in 22 quarters since. The position peaked at $206K in Q4 2025. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • AssetMark Inc held 5,779 shares of Castle Biosciences worth $142K as of Q1 2026.
  • AssetMark Inc bought 492 Castle Biosciences shares in Q1 2026, an estimated $16.1K.
  • Castle Biosciences made up ﹤0.01% of AssetMark Inc's portfolio in Q1 2026, its #1429 holding.
  • AssetMark Inc first reported a position in Castle Biosciences in Q4 2020 and has held it in 22 quarters since.
  • AssetMark Inc's Castle Biosciences position peaked at $206K in Q4 2025.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on AssetMark Inc's 13F filing for Q1 2026, filed 6 May 2026.